Related Experiment Video

Updated: Jan 19, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

807

Mechanism of action of rapalogues: the antiangiogenic hypothesis

Sandrine Faivre, Eric Raymond

    Expert Opinion on Investigational Drugs
    |October 17, 2008
    PubMed

    Insights

    Current rapalogues may primarily exert anti-angiogenic effects in hypervascularized tumors, rather than directly targeting cancer cells. Further translational research is needed to confirm this hypothesis and optimize drug development.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, proliferation, and apoptosis.
    • mTOR plays a critical role in the crosstalk between cancer cells, stromal cells, and endothelial cells.
    • Rapalogues have shown antitumor activity in clinical trials for hypervascularized tumors.

    Discussion:

    • The precise mechanism of action for rapalogues in tumors is unclear, specifically whether they target cancer cells directly or affect stromal components.
    • Understanding if rapalogues act as anti-angiogenic agents is crucial for refining their therapeutic applications and drug development strategies.
    • This study hypothesizes that the observed antitumor effects of rapalogues in hypervascularized tumors may stem primarily from their anti-angiogenic properties.

    Key Insights:

    • mTOR signaling is central to cancer and stromal cell interactions.
    • Rapalogues' efficacy in hypervascularized tumors warrants investigation into their anti-angiogenic potential.
    • Distinguishing between direct anticancer effects and anti-angiogenic mechanisms is key for rapalogue drug development.

    Outlook:

    • Further translational investigations are required to validate the proposed anti-angiogenic mechanism of rapalogues.
    • Clarifying the mechanism of action will inform future clinical trial design and patient selection for rapalogue therapy.
    • This research could lead to improved therapeutic strategies for managing hypervascularized tumors.

    More Related Videos

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

    Published on: July 20, 2019

    6.4K
    Rat Mesentery Angiogenesis Assay18:30

    Rat Mesentery Angiogenesis Assay

    Published on: June 18, 2011

    14.2K

    Related Concept Videos

    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
    3.3K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.6K
    Mechanism of Angiogenesis01:10

    Mechanism of Angiogenesis

    Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
    6.7K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    5.4K
    Experimental RNAi02:15

    Experimental RNAi

    RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
    7.3K
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    467